Drugs / Hyperpolarized Carbon 13 Alpha-ketoglutarate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05851378 | Apr 2023 → Jan 2026 | glioma | Robert Bok, MD, PhD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyperpolarized Carbon 13 Alpha-ketoglutarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05851378 ↗ |
| Route | Intravenous | “Given intravenously at time of imaging” NCT05851378 ↗ |